<DOC>
	<DOC>NCT00426296</DOC>
	<brief_summary>SHARE: Simple HAART with Abacavir, Reyataz, and Epivir</brief_summary>
	<brief_title>SHARE: Simple HAART With Abacavir, Reyataz, and Epivir</brief_title>
	<detailed_description>Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA &lt;50 copies/mL at entry</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<criteria>Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen Viral load &lt;50 copies/ml Viral load &gt;50 copies/ml Having taken more than one antiretroviral regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>HIV</keyword>
	<keyword>Reyataz</keyword>
	<keyword>atazanavir</keyword>
	<keyword>Norvir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>Boosted</keyword>
	<keyword>Lipodystrophy</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>